Creatine and women: what does the evidence actually show?
Creatine has accumulated one of the most robust evidence bases of any supplement, particularly for exercise performance and resistance training outcomes. It is also one of the most commercially noisy spaces in sports nutrition, where marketing claims consistently run ahead of what the trials actually show. For women specifically, there is now a growing body of evidence that is both encouraging and frequently misrepresented - either by the supplement industry overstating what is known, or by older clinical assumptions underselling it.
The honest picture requires separating what is well-established, what is biologically plausible but preliminary, and what remains genuinely uncertain. That separation looks different for women than it does for men, for reasons that are grounded in physiology rather than marketing.
Why women start from a different baseline
Creatine is synthesised in the body from three amino acids and stored primarily in skeletal muscle as phosphocreatine, where it serves as a rapid energy substrate during high-intensity effort. It is also obtained through diet, primarily from meat and fish. Women tend to have lower baseline muscle creatine stores than men on average, which reflects a combination of lower total muscle mass, lower habitual meat intake in many populations, and potentially some influence of sex hormones on creatine metabolism.
The practical consequence of lower baseline stores is potentially meaningful: the response window for supplementation may be wider. When creatine stores are already near saturation as in a high meat-consuming male athlete with extensive training history supplementation produces smaller marginal gains. When stores are lower, the scope for increase is greater. Vegetarians, vegans, and older adults consistently show the greatest absolute increases in muscle phosphocreatine with supplementation. For women as a broader category, the position is more qualified: lower baseline availability may increase the scope for response in some women, particularly those with lower habitual dietary creatine intake, but translating that physiological difference into reliably larger practical outcomes across female populations is not yet firmly established in the trial literature.
There is also some evidence that women may require relatively higher doses per kilogram of lean mass to achieve equivalent saturation compared to men, though this is not definitively established and standard dosing protocols appear effective in practice.
What the performance evidence shows
The performance evidence for creatine in women is substantially consistent with the broader literature. Creatine supplementation combined with resistance training produces improvements in muscle strength and lean mass. The mechanistic basis i.e. increased phosphocreatine availability for ATP resynthesis during maximal short-duration efforts is the same regardless of sex. The evidence in female populations, while smaller in volume than the male-dominant literature, points in the same direction.
What matters for performance outcomes is the training context. Creatine without progressive resistance training produces substantially smaller lean mass effects. The supplement augments training adaptation; it does not substitute for it. This is equally true for women and men, and is frequently lost in consumer-facing messaging that implies creatine produces muscle independently of the work required to build it. The effects observed in trials are often modest in absolute terms and are likely most meaningful in structured training or performance contexts rather than general fitness activity.
An initial weight increase of approximately 0.5 to 1.5 kilograms is common in the first week or two of supplementation. This reflects increased intramuscular water retention as creatine draws water into muscle cells, it is a normal physiological response and a sign of muscle creatine loading, not fat gain. This is worth knowing in advance, particularly as it is sometimes misinterpreted and occasionally used as a reason to discontinue a supplement that is working as expected.
The perimenopause and menopause context
This is where the evidence is most interesting and most actively developing. The clinical rationale for creatine in women during and after the menopause transition is biologically coherent and practically significant, though it is important to be clear about what is directly demonstrated in female-specific trials versus what is extrapolated from broader older-adult evidence combined with female physiological rationale.
The menopause transition involves a substantial decline in oestrogen, which affects muscle mass, bone density, strength, and cognitive function. Muscle loss accelerates during perimenopause and continues into the postmenopausal years, contributing to long-term functional decline and increased risk of falls and fractures. Creatine, combined with resistance training, is one of the better-supported strategies for attenuating these changes, based on broader older-adult evidence and emerging female-specific data rather than a mature perimenopausal trial literature.
Work by Smith-Ryan and colleagues, published in Nutrients in 2021, reviewed creatine across the female lifespan and identified the perimenopausal and postmenopausal period as one of the strongest contexts for use. The muscle and strength evidence in postmenopausal women is consistent with the broader older adult literature, where creatine combined with resistance training reliably improves muscle mass, strength, and functional outcomes such as walking speed and the ability to rise from a chair. These are not trivial endpoints. Sarcopenia, the progressive loss of muscle mass and function with age, is a significant contributor to reduced quality of life and loss of independence in older women.
The cognitive dimension during the menopause transition is mechanistically plausible but less well studied. Brain creatine metabolism plays a role in cerebral energy homeostasis, and cognitive changes during menopause, including difficulties with memory and processing speed are well-documented. Whether creatine supplementation can meaningfully buffer some of these changes is a reasonable hypothesis that is being explored, but the human trial evidence specific to this population and these outcomes is limited. The signal from the broader cognitive literature in older adults is consistent but modest, and should not be extrapolated with confidence to the specific perimenopausal context without further replication.
Cognitive effects: who actually benefits
The cognitive evidence for creatine is more nuanced than most summaries suggest. In healthy omnivores with normal dietary creatine intake under normal conditions, well-powered trials are generally null. The effect is concentrated in populations where brain creatine availability is likely lower: vegetarians and vegans (who obtain no dietary creatine), older adults, and people under conditions of cognitive stress, sleep deprivation, or hypoxia that impose acute demands on brain energy metabolism.
A meta-analysis by Prokopidis and colleagues in 2023 found a significant overall effect of creatine on memory, but this effect was driven substantially by studies in older adults and vegetarians. Pooling these with younger omnivores produces a result that can mislead in both directions overstating the benefit in replete populations and underselling it in those most likely to respond. The Prokopidis paper also reported moderate risk of bias and substantial heterogeneity across included studies, which means the overall cognitive signal, while real, is not clean. A subgroup-driven finding in a meta-analysis is not the same as a settled clinical recommendation, and more recent review work has argued that the theoretical basis for broad cognitive benefits is weaker than often assumed, with effects in healthy unstressed younger participants generally absent.
For a woman in her late forties or fifties with modest meat intake, the cognitive rationale for creatine is more biologically plausible than it would be for a younger omnivore with high habitual dietary intake -- but even in this group, the evidence should be characterised as suggestive rather than established. Context matters, and so does appropriate uncertainty.
Depression and mood: a preliminary adjunctive signal
A small body of evidence has examined creatine in the context of depression, largely as an adjunct to standard antidepressant treatment rather than as a standalone intervention. Several trials have reported improvements in depressive symptoms, and a number of these studies have been conducted in female populations. The mechanistic rationale involves the role of prefrontal phosphocreatine in mood regulation and emotional processing.
The evidence here is at an early and immature stage. Sample sizes are limited, replication is incomplete, and the findings come from adjunctive use alongside existing treatment, they should not be interpreted as evidence for routine use in mood disorders, and creatine is not supported as a first-line or standalone approach to depression by this literature. The signal is worth noting because it is biologically grounded and appears specifically in female populations, but "preliminary" is the accurate characterisation and it should be treated as a research direction rather than a clinical finding.
Forms and dosing
Creatine monohydrate is the appropriate choice. It has the largest evidence base by a substantial margin and has consistently matched or outperformed alternative forms - ethyl ester, buffered creatine, hydrochloride in direct comparison trials. Claims of superiority for these alternatives are driven by marketing rather than evidence.
Two protocols achieve equivalent outcomes. A loading protocol - 20g per day in four divided doses for five to seven days reaches saturation quickly. A non-loading protocol of 3 to 5g per day achieves the same saturation over approximately four weeks with less risk of gastrointestinal discomfort. The non-loading approach is generally better tolerated and practically sufficient unless there is a specific reason to saturate quickly. Once saturation is achieved, daily consistency matters more than precise timing relative to exercise. Taking creatine with a meal improves muscle uptake via insulin-mediated mechanisms.
Safety considerations
Creatine monohydrate is well-tolerated at standard doses with decades of research behind its safety profile. Long-term data beyond five years is limited, and that boundary on certainty is worth acknowledging even though the shorter-term record is reassuring. Supplementation raises plasma creatinine as a normal metabolic byproduct. This is benign but can be misread as a sign of impaired kidney function on a standard blood test, so it is worth informing a clinician if creatine use is ongoing when renal markers are being assessed.
Current evidence has not shown kidney harm in healthy individuals at standard doses, though the absence of demonstrated harm is not the same as confirmed long-term safety across all populations and durations. This does not apply to individuals with pre-existing kidney disease or conditions affecting creatine metabolism, who should seek clinical guidance before supplementing. Loading protocols can cause gastrointestinal discomfort in some people, which is largely avoided by the non-loading approach.
One unreplicated trial reported elevated dihydrotestosterone with creatine supplementation. This has not been confirmed in subsequent research and is insufficient to support a causal relationship with hair loss. It is worth noting for individuals with specific concerns about androgenic alopecia, but it does not represent established evidence of harm.
A note on the state of the female-specific evidence
It is worth being explicit about something that runs through much of this discussion. A significant portion of what can be said about creatine in women rests on two things combined: the broader creatine literature conducted largely in men, and female-specific physiological rationale for why the same mechanisms apply and may apply with particular force. That is a legitimate and often reliable basis for inference, but it is not the same as a large, well-powered female-only RCT programme. Such a programme does not yet exist for creatine. The evidence is growing, the direction is positive, and the biological coherence is strong but the degree of confidence that the article can reasonably carry is bounded by that reality.
What can reasonably be concluded
The evidence for creatine in women is strongest for muscle strength, lean mass, and functional outcomes in the context of resistance training effects consistent with the broader literature and particularly relevant during and after the menopause transition. Women with low habitual dietary creatine intake, including vegetarians, vegans, and older women, represent the populations where response is most likely to be meaningful.
The cognitive rationale is grounded in older women and those with low dietary creatine intake, more uncertain in younger omnivores, and should be characterised as suggestive rather than established even in the more plausible subgroups. The mood signal is preliminary, adjunctive, and not yet a basis for clinical use.
Creatine monohydrate at 3 to 5g daily, taken consistently, remains the evidence-based approach. The commercial narrative around creatine in women has expanded faster than the clinical evidence, but the underlying evidence is more substantive than sceptics sometimes assume provided it is read at the confidence level the trials actually support, rather than the one the marketing implies.
For the full evidence summary including trial details, effect sizes, and population-specific evidence ratings, see the Creatine entry in the Evidentia library.